Enanta Pharmaceuticals (NASDAQ:ENTA) Target Raised by Royal Bank of Canada to $74.00

StockMarketDaily.co reports: Enanta Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Enanta Pharmaceuticals stock Target Raised by   Royal Bank of Canada on 10/20/2021. In a note to investors, the firm issued a new target price of $74.00. The analysts previously had $58.00 target price.

View More Enanta Pharmaceuticals (NASDAQ:ENTA) Target Raised by Royal Bank of Canada to $74.00

Enanta Pharmaceuticals (ENTA) Upgraded by Zacks Investment Research to Buy

Enanta Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Enanta Pharmaceuticals Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Enanta Pharmaceuticals (ENTA) Upgraded by Zacks Investment Research to Buy

Earnings Scorecard & Analyst Reports Enanta Pharmaceuticals (NASDAQ:ENTA)

Earnings results for Enanta Pharmaceuticals , Analyst Opinion on Enanta Pharmaceuticals , Earnings and Valuation of (NASDAQ:ENTA), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings Scorecard & Analyst Reports Enanta Pharmaceuticals (NASDAQ:ENTA)

How Have the Numbers Shaped Up for Enanta Pharmaceuticals (NASDAQ:ENTA)

Earnings results for Enanta Pharmaceuticals , Analyst Opinion on Enanta Pharmaceuticals , Earnings and Valuation of (NASDAQ:ENTA), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More How Have the Numbers Shaped Up for Enanta Pharmaceuticals (NASDAQ:ENTA)